GB202319953D0 - Tablet formulations involving alvelestat - Google Patents

Tablet formulations involving alvelestat

Info

Publication number: GB202319953D0
Authority: GB; United Kingdom
Prior art keywords: alvelestat; tablet formulations; formulations involving; involving; tablet
Prior art date: 2023-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB2319953.2A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mereo Biopharma 4 Ltd

Original Assignee

Mereo Biopharma 4 Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2023-12-22

Filing date

2023-12-22

Publication date

2024-02-07

2023-12-22 Application filed by Mereo Biopharma 4 Ltd filed Critical Mereo Biopharma 4 Ltd

2023-12-22 Priority to GBGB2319953.2A priority Critical patent/GB202319953D0/en

2024-02-07 Publication of GB202319953D0 publication Critical patent/GB202319953D0/en

2024-12-20 Priority to PCT/GB2024/053187 priority patent/WO2025133629A1/en

Status Ceased legal-status Critical Current

Links

QNQZWEGMKJBHEM-UHFFFAOYSA-N 6-methyl-5-(2-methylpyrazol-3-yl)-n-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1N(C=2C=C(C=CC=2)C(F)(F)F)C(C)=C(C=2N(N=CC=2)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=O)C=N1 QNQZWEGMKJBHEM-UHFFFAOYSA-N 0.000 title 1
229950005666 alvelestat Drugs 0.000 title 1
239000007916 tablet composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)

GBGB2319953.2A 2023-12-22 2023-12-22 Tablet formulations involving alvelestat Ceased GB202319953D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB2319953.2A GB202319953D0 (en)	2023-12-22	2023-12-22	Tablet formulations involving alvelestat
PCT/GB2024/053187 WO2025133629A1 (en)	2023-12-22	2024-12-20	Tablet formulations involving alvelestat

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB2319953.2A GB202319953D0 (en)	2023-12-22	2023-12-22	Tablet formulations involving alvelestat

Publications (1)

Publication Number	Publication Date
GB202319953D0 true GB202319953D0 (en)	2024-02-07

Family

ID=89767956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB2319953.2A Ceased GB202319953D0 (en)	2023-12-22	2023-12-22	Tablet formulations involving alvelestat

Country Status (2)

Country	Link
GB (1)	GB202319953D0 (en)
WO (1)	WO2025133629A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0302486D0 (en)	2003-09-18	2003-09-18	Astrazeneca Ab	Novel compounds
TW201036957A (en)	2009-02-20	2010-10-16	Astrazeneca Ab	Novel salt 628
US20220354833A1 (en) *	2019-09-17	2022-11-10	Mereo Biopharma 4 Limited	Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
DK4106757T3 (en)	2020-04-16	2023-10-23	Mereo Biopharma 4 Ltd	METHODS INVOLVING THE NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR THE TREATMENT OF AIRWAY DISEASE MEDIATED BY ALPHA-1-ANTITRYPSIN DEFICIENCY

2023
- 2023-12-22 GB GBGB2319953.2A patent/GB202319953D0/en not_active Ceased
2024
- 2024-12-20 WO PCT/GB2024/053187 patent/WO2025133629A1/en active Pending

Also Published As

Publication number	Publication date
WO2025133629A1 (en)	2025-06-26

Publication	Publication Date	Title
SG11202109102PA (en)	2021-09-29	Pharmaceutical formulations
GB202005282D0 (en)	2020-05-27	Pharmaceutical Formulations
IL286942A (en)	2021-12-01	Vaginal tablet formulation
IL314206A (en)	2024-09-01	Pharmaceutical formulation
GB202319953D0 (en)	2024-02-07	Tablet formulations involving alvelestat
PT4171572T (en)	2025-06-16	Dispersible tablet formulations comprising dolutegravir
GB202103785D0 (en)	2021-05-05	Formulations
GB202018889D0 (en)	2021-01-13	Formulations
GB202009685D0 (en)	2020-08-12	Formulations
GB202001439D0 (en)	2020-03-18	Drug formulations
CA235950S (en)	2025-02-20	Tablet
GB202307626D0 (en)	2023-07-05	Pharmaceutical formulations
ZA202212663B (en)	2023-07-26	Pharmaceutical formulations
IL308250A (en)	2024-01-01	Pharmaceutical formulations
GB202112820D0 (en)	2021-10-20	Pharmaceutical formulations
PH32023050572S1 (en)	2023-10-11	Tablet
IL321617A (en)	2025-08-01	Bezuclastinib formulations
GB202315863D0 (en)	2023-11-29	Formulations
GB202307059D0 (en)	2023-06-28	Formulations
GB202216961D0 (en)	2022-12-28	5-meo-mt formulations
GB202003108D0 (en)	2020-04-15	Pharmaceutical formulations
IL321640A (en)	2025-08-01	Pharmaceutical formulation
IL319214A (en)	2025-04-01	Pharmaceutical formulation
GB202216467D0 (en)	2022-12-21	Pharmaceutical formulation
GB202115121D0 (en)	2021-12-08	Formulations

Legal Events

Date	Code	Title	Description
2025-02-05	AT	Applications terminated before publication under section 16(1)